Retatrutide Dosage Timing and Meal Interactions Unlike some oral metabolic compounds, retatrutide dosage timing is not meal-dependent
The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
Alexandra Sowa, MD SoWell Founder Dual Board-Certified Obesity & Internal Medicine Physician Frequently Asked Questions What are FSA and HSA accounts
Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics
Chronic stress and poor sleep elevate cortisol chronically, which can partially counteract the appetite-suppressing effects of GLP-1 therapy
Study population The source population encompassed all Danish citizens aged 65 years and older with type-2 diabetes between 2007 and 2018 [11]
